Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29528196 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MAPTKDM4ETDP1LMNA | |
| Hydrogen Sulfide SCHEMBL21332270 | 0.99 | ALDH1A1 (0.49) | ALDH1A1MAPTKDM4ETDP1LMNA | |
| SCHEMBL21332271 | 0.97 | MAPT (0.48) | ALDH1A1MAPTKDM4ETDP1LMNA | |
| SCHEMBL1137313 | 0.93 | ALDH1A1 (0.44) | ALDH1A1MAPTKDM4ETDP1LMNA | |
| SCHEMBL14028790 | 0.89 | KDM4E (0.45) | ALDH1A1MAPTKDM4ETDP1LMNA | |
| SCHEMBL20471548 | 0.85 | TDP1 (0.42) | ALDH1A1MAPTKDM4ETDP1LMNA | |
| SCHEMBL16541405 | 0.85 | ALDH1A1 (0.43) | ALDH1A1MAPTKDM4ETDP1LMNA | |
| SCHEMBL17583237 | 0.85 | KDM4E (0.49) | ALDH1A1MAPTKDM4ETDP1LMNA | |
| SCHEMBL18700363 | 0.84 | KMT2A (0.43) | ALDH1A1MAPTKDM4ETDP1LMNA | |
| SCHEMBL16456689 | 0.83 | CXCR1 (0.51) | ALDH1A1MAPTKDM4ETDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049622-B2 | Targeted transposition for use in epigenetic studies | ACTIVE MOTIF, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-11850287-B2 | Heterocyclic acyl hydrazone linkers, methods and uses thereof | ONTARIO INSTITUTE FOR CANCER SEARCH (OICR) (CA) | 2023-12-26 | — | — | US | disclosed |
| US-20230330244-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) INHIBITOR-CONJUGATES AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2023-10-19 | — | — | US | disclosed |
| US-20230330244-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) INHIBITOR-CONJUGATES AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2023-10-19 | — | — | US | disclosed |
| US-11576981-B2 | Acyl hydrazone linkers, methods and uses thereof | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2023-02-14 | — | — | US | disclosed |
| EP-2999784-B2 | TARGETED TRANSPOSITION FOR USE IN EPIGENETIC STUDIES | ACTIVE MOTIF INC (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220356465-A1 | TARGETED TRANSPOSITION FOR USE IN EPIGENETIC STUDIES | MIDCAP FINANCIAL TRUST | 2022-11-10 | — | — | US | disclosed |
| US-20220313832-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) INHIBITOR-CONJUGATES AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-10-06 | — | — | US | disclosed |
| EP-3983405-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) INHIBITOR-CONJUGATES AND USES THEREOF | Ontario Institute for Cancer Research (OICR) (CA) | 2022-04-20 | — | — | EP | disclosed |
| US-11306307-B2 | Targeted transposition for use in epigenetic studies | ACTIVE MOTIF, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3720842-A1 | ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | Ontario Institute For Cancer Research (CA) | 2020-10-14 | — | — | EP | disclosed |
| US-20200299678-A1 | TARGETED TRANSPOSITION FOR USE IN EPIGENETIC STUDIES | ACTIVE MOTIF, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| EP-3712267-A1 | TARGETED TRANSPOSITION FOR USE IN EPIGENETIC STUDIES | Active Motif, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| US-10689643-B2 | Targeted transposition for use in epigenetic studies | ACTIVE MOTIF, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| WO-2019170710-A2 | CHEMOSELECTIVE THIOL-CONJUGATION WITH ALKENE OR ALKYNE-PHOSPHONOTHIOLATES AND -PHOSPHONATES | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019109188-A1 | ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2019-06-13 | — | — | WO | disclosed |
| US-20180010121-A9 | TARGETED TRANSPOSITION FOR USE IN EPIGENETIC STUDIES | ACTIVE MOTIF, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| US-20160115474-A1 | TARGETED TRANSPOSITION FOR USE IN EPIGENETIC STUDIES | ACTIVE MOTIF, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| EP-2999784-A1 | TARGETED TRANSPOSITION FOR USE IN EPIGENETIC STUDIES | Active Motif, Inc. (US) | 2016-03-30 | — | — | EP | disclosed |
| WO-2014190214-A1 | TARGETED TRANSPOSITION FOR USE IN EPIGENETIC STUDIES | ACTIVE MOTIF, INC. (US) | 2014-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220313832-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) INHIBITOR-CONJUGATES AND USES THEREOF | NAMPT, NAPRT, NNT | ALDH1A1 593/4885MAPT 193/4885KDM4E 3925/4885 |
| US-20230330244-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) INHIBITOR-CONJUGATES AND USES THEREOF | NAMPT, NAPRT, NNT | ALDH1A1 610/4885MAPT 200/4885KDM4E 3993/4885 |
| US-11850287-B2 | Heterocyclic acyl hydrazone linkers, methods and uses thereof | HDAC6, C9, AADAC | ALDH1A1 178/4885MAPT 2025/4885KDM4E 1071/4885 |
| US-11576981-B2 | Acyl hydrazone linkers, methods and uses thereof | AADAC, HDAC8, KAT8 | ALDH1A1 169/4885MAPT 3082/4885KDM4E 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.